Verition Fund Management’s VanEck Biotech ETF BBH Stock Holding History

Verition Fund Management’s Portfolio BBH Stock Details BBH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,252	Closed	-$657K	–	2537
2021 Q3	$657K	Buy	+3,252	New	+$683K	0.01%	1105
2021 Q1	–	Sell	-2,459	Closed	-$417K	–	1543
2020 Q4	$417K	Buy	+2,459	New	+$405K	﹤0.01%	722
2020 Q1	–	Sell	-5,056	Closed	-$705K	–	622
2019 Q4	$705K	Buy	+5,056	New	+$664K	0.01%	552
2014 Q3	–	Sell	-12,484	Closed	-$1.19M	–	723
2014 Q2	$1.19M	Sell	12,484 -3,483	-22%	-$312K	0.13%	102
2014 Q1	$1.45M	Buy	+15,967	New	+$1.55M	0.22%	75

Other funds holding BBH

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

MJRIC

Mogy Joel R Investment Counsel Beverly Hills, California $1.75B AUM 17.81% 1-Year Est. Return

MCM

Murphy Capital Management Bedminster, New Jersey $720M AUM 9.22% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

Verition Fund Management's BBH Position: Q4 2021 in Review

Verition Fund Management sold out of VanEck Biotech ETF (BBH) in Q4 2021, closing a stake of 3,252 shares — an estimated $657K sold.

Verition Fund Management first reported a position in BBH in Q1 2014 and held it in 5 quarters. The position peaked at $1.45M in Q1 2014. 126 funds tracked by Wall St. Rank hold BBH as of Q4 2021.

Verition Fund Management reported no remaining VanEck Biotech ETF position as of Q4 2021 after selling out during the quarter.
Verition Fund Management sold 3,252 VanEck Biotech ETF shares in Q4 2021, an estimated $657K.
Verition Fund Management first reported a position in VanEck Biotech ETF in Q1 2014 and held it in 5 quarters.
Verition Fund Management's VanEck Biotech ETF position peaked at $1.45M in Q1 2014.
126 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q4 2021.

Based on Verition Fund Management's 13F filing for Q4 2021, filed 14 Feb 2022.